At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
luspaterceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension Study To Evaluate The Long-Term Effects Of ACE-536 In Patients With β-Thalassemia Previously Enrolled In Study A536-04
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA·interventional·Posted Oct 20, 2014·Updated Jul 18, 2024
In Brief
A Phase 2 clinical trial evaluating luspatercept for β-Thalassemia. Completed, enrolled 51 participants across 7 sites in 2 countries.
Detailed Summary
Study A536-06 (MK-6143-004) is an open-label extension study for participants previously enrolled in study A536-04 (NCT01749540), to evaluate the long-term safety and tolerability of luspatercept in adult participants with beta-thalassemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Conditionsβ-Thalassemia
CountriesGreece, Italy
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartOct 2014
Primary CompletionJun 2020
TodayJul 2026
First PostedOct 20, 2014
Enrollment StartOct 20, 2014
Primary CompletionJun 18, 2020
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.7 years ago
Interventions
luspaterceptdrug
subcutaneous injection